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Empowering heliotherapy aims at clinical healing and 
improved coping with psoriasis and atopic dermatitis, 
but evidence of long-term effects is scarce. We studied 
the effect of 2-week empowering heliotherapy in the Ca-
nary Islands on clinical outcome and quality of life in 22 
psoriasis and 13 atopic dermatitis patients. Empower-
ment consisted of meeting peers, sharing experiences 
and performing physical and mental practices. Using the 
self-administered PASI (SAPASI) psoriasis was alleviated 
statistically significantly during heliotherapy (p < 0.001), 
and the treatment effect was still detectable 3 months la-
ter (p < 0.001). Atopic dermatitis was improved (p < 0.001) 
when assessed with the patient-oriented SCORAD (PO-
SCORAD), and the effect was still obvious 3 months la-
ter (p = 0.002). During heliotherapy the dermatology life 
quality index (DLQI) improved in both groups (p < 0.001), 
persisting in atopic patients for up to 3 months (p = 0.002), 
but not in psoriasis patients. In conclusion, a 2-week em-
powered heliotherapy showed a long-lasting improvement 
in psoriasis and atopic dermatitis disease activity, and also 
in the quality of life of atopic patients. Key words: vitamin 
D; ultraviolet B radiation; SAPASI; PO-SCORAD; DLQI.
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Psoriasis (PS) and atopic dermatitis (AD) are chronic 
inflammatory skin diseases with a negative impact on 
quality of life (QoL) (1, 2). PS and AD can be treated 
with sunbathing, i.e. heliotherapy (HT), alleviating the 
physical and psychological fatigue of patients (3–5). The 
Nordic health authorities have funded 
HT courses since the 1970s (5, 6). 
Recently, emphasis has moved from 
HT to empowerment of patients and 
coping with the disease. Therefore, 
HT was renovated to meet these go-
als. The present HT model consists of 
meeting peers, sharing experiences, 
adopting a healthy life style, exerci-
sing practices, improving physical, 
psychological and social wellbeing and coping with the 
disease guided by health care experts. The staff consists 
of experienced nurses, a physiotherapist and a psycholo-
gist. Because less emphasis is put on HT, the treatment 
results could differ from those of traditional HT. 
To our knowledge, no earlier study has assessed 
sunbathing habits, QoL or vitamin D (VD) changes in 
parallel for PS and AD patients receiving HT. The aim 
of the study was to monitor the efficacy of a 2-week 
empowered HT on personal UV exposure, clinical 
outcome, QoL and VD balance in PS and AD patients 
attending the same course. We also performed a follow-
up 3 months after the HT course.
MATERIAL AND METHODS
Patients and heliotherapy course
The Finnish Psoriasis Association and the Finnish Central Orga-
nisation for Skin Patients together arranged a 2-week HT course 
for PS and AD patients in Puerto Rico (27°N, 15°W), the Canary 
Islands, Spain from 27th October to 10th November in 2012. Inclu-
sion criteria were psoriasis or atopic dermatitis without demanding 
any minimum severity scorings, subjects had to be aged 18 or 
older and have a referral from a doctor. Exclusion criteria were 
photosensitivity, Fitzpatrick’s skin photo-type I, photosensitising 
drugs, excessive alcohol use, drug abuse, severe cardiovascular 
diseases, unbalanced diabetes or mental disorders (7). The course 
included an education day before HT and a reunion weekend 3 
months afterwards. The amount to be paid by the participants was 
€400, the total cost per patient being €2,450. Twenty-two PS and 
13 AD patients took part in the study (Table I). Fifteen patients 
had psoriatic arthritis and 5 of them used biologic drugs, 3 of these 
patients also used methotrexate. Two patients had methotrexate 
as a monotherapy. During HT the patients were allowed to use 
their routine topical medication. Nineteen patients (14 PS, 5 AD) 
used VD supplementation before HT, on mean 23 µg (range 5–50 
µg) daily, but not during HT or 3 months after it.
The patients had their sunbathing plans adjusted for their 
Fitzpatrick’s skin types. The first solar exposure times ranged 
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Table I. Demographics of patients with psoriasis and atopic dermatitis (AD), and UV 
radiation doses received during a two-week heliotherapy course
Psoriasis (n = 22) AD (n = 13) p-value
Male/Female, n 8/14 0/13 0.013
Age, years, mean ± SD (range) 52 ± 10 (34–68) 44 ± 17 (21–74) 0.069
Body mass index, mean ± SD (range) 28.2 ± 6.2 (17.1–41.9) 27.1 ± 6.9 (19.1–39.8) 0.643
Fitzpatrick’s skin type, II/III/IV 6/15/1 5/8/0 0.615
UV dosimeter (SED), mean ± SD (range) 30 ± 16 (22.4–38.5)a 43 ± 16 (32.1–53.9)b 0.062
aFrom 18 patients, bFrom 12 patients. SED: standard erythema dose.
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from 20–90 min for PS and 15–30 min for AD patients. Both 
sides of the body were exposed during sunbathing. The time was 
increased within a week to 90–300 min for PS and to 120 min 
for AD patients. The scheduled sunbathing treatments were done 
without sunscreen in the mornings or afternoons. Sunscreen was 
applied liberally thereafter. The supporting program included 
teaching self-management and a healthy life style as well as group 
conversations with a psychologist, altogether for 14 h for both 
groups. Physical exercise included water sports, trekking and 
gymnastics for 24 h for the PS group and 11 h for the AD group.
The Ethics Committee of the Tampere University Hospital 
approved the study protocol. All patients gave their informed 
consent before the study. 
UV exposure measurements
To measure the personal UVB dose received by the skin during 
HT the patients wore personal UV dosimeters (VioSpor blue line 
Type III, BioSense, Bornheim, Germany), one meter was used for 
week one and another for week two (8, 9). The meters detect a 
dose ranging from 1.5 to 90 Standard Erythema Dose (SED). The 
dosimeters were attached to the patients’ upper arms or wrists with 
straps and during sunbathing they were placed on towels beside 
the patients (10). Eighteen PS and 12 AD patients wore dosime-
ters. The ambient maximum solar UV-irradiance was measured 
as a mean dose from 2 VioSpor Type III dosimeters at a time. 
The meters were put in an open place and replaced every other 
day to avoid overexposure. The Spanish Agency of Metereology 
(Agencia Estatal de Metereologica; www.aemet.es) supplied the 
global solar UV irradiance data from the nearby (distance 15 km) 
Maspalomas C. Insular Turismo weather station. The first HT 
week was rainy and cloudy and the second HT week was sunny. 
During the HT maximum UV index varied between 5 and 8.
Assessment of disease activity
The PS patients filled out the Self-Administered Psoriasis 
Area and Severity Index (SAPASI) and AD patients the Patient 
Oriented Scoring of Atopic Dermatitis (PO-SCORAD) to fol-
low the disease activity (11, 12). Disease severity and pruritus 
were assessed globally using the Visual Analogue Scale (VAS) 
(13). The Dermatology Life Quality Index (DLQI) was used 
to assess the change in the QoL (14). All measures were filled 
out 3 times: at the onset, at the end and 3 months after HT. 
Serum 25-hydroxyvitamin D measurements 
VD samples were taken immediately before, at the end and 
3 months after HT. The sera were deep-frozen and stored at 
–20°C. Analysis of 25-hydroxyVD was performed in duplicates 
using radioimmunoassay (Immunodiagnostic Systems, Boldon, 
UK), as described earlier (15).
Statistics
The data are presented as means with standard deviations (SD) or 
as counts with percentages. Confidence intervals (95% CI) were 
obtained by bias-corrected bootstrapping (5,000 replications) 
Statistical comparisons were made by using analysis of t-test, co-
variance (ANCOVA). In the case of violation of the assumptions 
(e.g. non-normality), a bootstrap type test was used. Longitudinal 
measures for continuous outcomes were analysed using a bootstrap 
type generalised estimating equations (GEE) model. GEE were 
developed as an extension of the general linear model to analyse 
longitudinal and other correlated data. GEE models take into ac-
count the correlation between repeated measurements in the same 
subject; models do not require complete data and can be fit even 
when there are not observations at all time-points for individuals. 
No adjustment was made for multiple testing. When comparing 
increases in VD concentrations, the model was standardised by age, 
sex and body mass index (BMI). Pearson’s χ2 test was used when 
comparing nominal data. The STATA 13.1, StataCorp LP (College 
Station, TX, USA) statistical package was used for the analyses.
RESULTS
UV exposures during heliotherapy 
According to personal dosimeter measurements the PS 
patients received a mean UV dose of 30 ± 16 SED and 
the AD patients 43 ± 16 SED during HT (Table I) show-
ing no significant difference (p = 0.062). The respective 
cumulative ambient two-week UV irradiance was 244 
SED measured by VioSpor III dosimeters and 303 SED 
using the UV records obtained from the Maspalomas 
C. Insular Turismo station.
Disease activity and quality of life at the end of heliotherapy
HT was statistically equally effective in PS and AD 
when disease activity was scored (Table II). Mean 
SAPASI decreased from 6.7 by 4.9 units (p < 0.001) and 
PO-SCORAD from 30.6 by 19.5 units (p < 0.001). Four 
Table II. Clinical outcome of a two-week heliotherapy course in patients with psoriasis and atopic dermatitis (AD) measured by Self-
Administered Psoriasis Area and Severity Index (SAPASI) or PO SCORAD scores, and by visual analogue scores of severity and pruritus. 
Vitamin D concentrations were measured at the same time points as the clinical outcome scores. Mean ± SD and change (Δ) of mean 
value compared to Day 0
Psoriasis (n = 22) AD (n =13)
Day 0 Δ Week 2 Δ Week 14 Day 0 Δ Week 2 Δ Week 14
SAPASI/PO SCORAD (95% CI) 6.7 ± 5.6 
(4.2–9.2)
–4.9*** 
(–6.8 to –3.0)
–3.1*** 
(–4.7 to –1.4)
30.6 ± 17.6 
(20.0–41.3)
–19.5*** 
(–26.2 to –12.9)
–10.0** 
(–16.3 to –3.8)
Visual analogue score global (95% CI) 3.9 ± 2.2 
(2.9–4.9)
–2.0*** 
(–2.8 to –1.0)
–1.4** 
(–2.3 to –0.4)
3.4 ± 2.2 
(2.1–4.7)
–1.8*** 
(–2.4to –1.2)
–0.9 
(–2.0–0.2)
Visual analogue score pruritus (95% CI) 3.1 ± 2.2 
(2.1–4.1)
–2.2*** 
(–3.1 to –1.4)
–0.9 
(–1.9–0.1)
3.7 ± 2.5 
(2.2–5.3)
–2.2*** 
(–3.1 to –1.4)
–0.9 
(–2.3–0.4)
Dermatology Life Quality Index (95% CI) 6.1 ± 3.3 
(4.7–7.6)
–4.3*** 
(–5.5 to –3.1)
–0.8 
(–2.8–1.2)
7.2 ± 4.8 
(4.3–10.0)
–5.3*** 
(–7.3 to–3.4)
–3.2** 
(–5.2 to –1.2)
Vitamin D, nmol l–1 (95% CI) 86.6 ± 20.0 
(77.8–95.5)
13.8*** 
(8.6–19.0)
0.4a 
(–5.2–6.8)
84.1 ± 16.0b 
(73.4–94.9)
20.5*** 
(14.0–25.6)
–3.1c 
(–10.0–4.0)
**p < 0.01, ***p < 0.001 compared to heliotherapy day 0 values. 
a20 patients; b11 patients; c10 patients.
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PS but none of the AD patients experienced complete 
clearance, and 75% clearance was seen in 13 (59%) PS 
and 2 (15%) AD patients. Using the VAS scales there 
was significant improvement in disease severity and 
pruritus in both groups (Table II). QoL was improved 
showing a decrease in mean DLQI score from 6.1 by 
4.3 units (p < 0.001) in PS patients and from 7.2 by 5.3 
units (p < 0.001) in AD patients (Table II). At onset of 
HT no PS or AD patient was VD-insufficient, defined 
as 25(OH)D3 < 50 nmol l–1. During HT the VD con-
centrations increased significantly (p < 0.001, Table II) 
and equally (p = 0.56) in both patient groups.
Disease activity and quality of life after heliotherapy
At the follow-up 3 months after HT, the treatment effect 
significantly persisted when compared to initial scores 
(Table II). The decrease in SAPASI was 3.1 (p < 0.001) 
and in PO-SCORAD 10.0 (p = 0.002). Using the VAS 
the global disease severity also remained decreased 
(p = 0.004) in PS patients but not (p = 0.11) in AD patients. 
The VAS scores depicting pruritus had returned close to 
baseline levels both in PS (p = 0.058) and AD (p = 0.17) 
patients (Table II). In PS patients the 3-month follow-up 
DLQI scores had dropped to baseline (p = 0.43), but in 
the AD patients it remained improved (p = 0.002) (Table 
II). The VD concentrations had decreased in both the PS 
and AD patients close to the pre-HT values (Table II).
DISCUSSION
The results showed PS to improve statistically highly 
significantly during empowering HT, the mean SAPASI 
reducing by 73%. Complete clearance was reached in 
18% and 75% SAPASI clearance in 59% of the patients. 
The mean initial SAPASI score of 6.7 was markedly lo-
wer compared to the PASI or SAPASI scores of previous 
studies (16–19) indicating a mild disease, but 7 patients 
were using systemic drugs. Use of methotrexate or bio-
logic drugs should however not dampen the effect of HT 
since both have synergistic effects with UVB irradia-
tion (20, 21). HT reduced the PS scorings only slightly, 
which could be due to the short duration of HT, or the 
insensitivity of SAPASI as regards a mild disease state. 
In a study by Wahl et al. (17) the mean SAPASI remained 
decreased by 21.1% 4 months after HT, whereas in our 
study the reduction was 46.3% at the 3-month follow-up 
visit. It is not known whether the persisting improvement 
of the SAPASI in our patients was due to the enhanced 
educative contents of the course. 
In AD patients the mean PO-SCORAD score impro-
ved statistically significantly from 30.6 to 11.1 but did 
not show complete clearance in any of the patients, and 
only 15% reached 75% clearance. SAPASI and PO-
SCORAD are not comparable with each other, because 
PO-SCORAD includes subjective parameters in addition 
to visible signs. At the end of HT there were patients with 
no visible eczema, but due to pruritus or sleep disturban-
ces the PO-SCORAD did not show complete clearance. 
We used the DLQI measure to make a parallel as-
sessment for the QoL of both PS and AD patients. The 
improvement of QoL in the AD patients seemed to be 
more long-lasting than in the PS patients, but direct 
between-groups comparisons are not justified due to 
limited sample size in this study (22, 23). The PS and 
AD patient groups also differed significantly for gender 
(p = 0.013), and there were only females in the AD group. 
This could have influenced the results, because women 
have been shown to comply better with topical treatments 
than men (24). In this study, the size of the group as well 
as inclusion and severity of the patients were in the hands 
of the patient associations depicting the real life situa-
tion, rather than a strict experimental research protocol. 
The persistent long-term (up to 3-month) statistically 
significant improvement of DLQI among AD patients 
surprised us, because this contradicted the VAS scores 
measuring disease severity and pruritus. The VAS scores 
had returned to baseline. This discrepancy could be due to 
pruritus affecting the QoL of atopic patients more than the 
DLQI scores can show. It is important to use more than 
one measure in parallel to increase reliability. An inte-
resting measure, which we unfortunately were not aware 
of earlier, is the Health Education Impact Questionnaire 
(25). This was used in a recently published study of Wahl 
et al. (25), however also in this study the educational 
impact of empowering HT was a challenge (25). 
PS patients could be more risk-taking and prone to 
higher UV doses than AD patients (26, 27), but it turned 
out that AD patients received a higher dose in fewer 
hours. This could be explained by the different outdoor 
activities of the groups (28). Ambient irradiance is also 
highly dependent on the season. This became obvious 
in our earlier study where the personal UV dosimeter 
exposures of AD patients on two-week HT were 75 SED 
in January and 131 SED in March (9). The 30 SED and 
43 SED UV doses of our PS and AD patients reflect both 
the lower UV index of November season and unfortunate 
weather conditions of the first HT week, which probably 
affected the clearance of the skin diseases.
No patient was VD insufficient at the onset (Table II). 
Despite this, HT improved the VD status statistically 
significantly in both patient groups, 13.8 nmol l–1 for PS 
and 20.5 nmol l–1 for AD having received on mean 30 
SED and 43 SED respectively. Sunlight seems to be a 
very potent VD inductor even in subjects who showed 
no VD deficiency.
The empowering HT model is a response to public 
pressures stressing patients’ own responsibility and 
self-management for their care. New courses run by 
the patient organisations focus more on empowerment 
than clearance of the disease. Wahl et al. (25) studied 
the effect of climate therapy on self-management in 
PS patients, and our study focused also on AD pa-
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tients showing that both PS and AD were statistically 
significantly improved (25). In our past study HT was 
regarded cost-effective for the high indirect costs only 
for patients with severe psoriasis (29). Similar to the 
Norwegian study (25) we were unable to confirm long-
term improvement of QoL in PS patients (25). 
To conclude, UV doses received by PS and AD pa-
tients were comparable showing no obvious differen-
ces. The empowering HT cleared the skin symptoms 
statistically significantly, but in the long run did not 
improve the QoL of PS patients. In PS patients the 
decrease in disease severity expressed using the VAS 
seemed more long-lasting than in AD patients. A two-
week HT improved VD status statistically significantly 
even in non-VD deficient and substituted individuals.
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